Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
England’s NHS will fund ruxolitinib cream for teens and adults with facial vitiligo, the first approved treatment in the UK.
The NHS in England will now fund ruxolitinib cream (Opzelura) for patients aged 12 and over with non-segmental vitiligo affecting the face, marking the first approved treatment for the condition in the UK.
NICE approved the topical JAK inhibitor after a revised pricing agreement, citing strong clinical benefits and value for money.
The cream, applied twice daily, helps restore skin pigmentation by targeting the immune system’s attack on melanocytes, with trials showing significantly greater repigmentation than placebo.
It is recommended for those who haven’t responded to or cannot use first-line treatments.
The decision, welcomed by patient advocates, could benefit over 80,000 people and addresses a long-standing unmet medical need, particularly for those with darker skin tones and significant psychosocial impacts.
El NHS de Inglaterra financiará la crema ruxolitinib para adolescentes y adultos con vitiligo facial, el primer tratamiento aprobado en el Reino Unido.